CymaBay Therapeutics (CymaBay Therapeutics) GF Score : 20/100 (As of Jun. 05, 2024)

View and export this data going back to 2014. Start your Free Trial

What is CymaBay Therapeutics GF Score?

CymaBay Therapeutics has the GF Score of 20, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes CymaBay Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of CymaBay Therapeutics's GF Score

For the Biotechnology subindustry, CymaBay Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CymaBay Therapeutics's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CymaBay Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where CymaBay Therapeutics's GF Score falls into.

CymaBay Therapeutics (NAS:CBAY) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

CymaBay Therapeutics GF Score Related Terms

Thank you for viewing the detailed overview of CymaBay Therapeutics's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

CymaBay Therapeutics (CymaBay Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CymaBay Therapeutics Inc (NAS:CBAY) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

C0I:Germany

Address

7575 Gateway Boulevard, Suite 110, Newark, CA, USA, 94560

Website

https://www.cymabay.com

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).

Executives

Charles Mcwherter	officer: Chief Scientific Officer	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Daniel Menold	officer: Vice President, Finance	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Paul T Quinlan	officer: General Counsel	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Janet Dorling	director	C/O ACHAOGEN, INC., 1 TOWER PLACE, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Sujal Shah	director, officer: Chief Executive Officer	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Kurt Von Emster	director	601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Harish Shantharam	officer: Chief Financial Officer	7575 GATEWAY BLVD, NEWARK CA 94560
Dennis D Kim	officer: Chief Medical Officer	C/O EMERALD BIOSCIENCE, INC., 130 NORTH MARINA DRIVE, LONG BEACH CA 90803
Eric Lefebvre	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Thomas G Wiggans	director
Lewis J Stuart	officer: Chief Commercial Officer	3172 PORTER DRIVE, PALO ALTO CA 94304
Venbio Select Advisor Llc	10 percent owner	110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh	10 percent owner	C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Carl Goldfischer	director	161 WEST 61ST STREET, NEW YORK NY 10022
Robert James Wills	director	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103